Announcements Trials
Browse Landscape

Status

Active not recruiting 3Withdrawn 2Unknown 2Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 76Neoplasm Metastasis 8Metastatic Castration Resistant Prostate Cancer 5Breast Neoplasms 5Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Salivary Glands Tumors 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Newly Diagnosed Oligometastatic Prostate Cancer 1Metastatic Hormone Refractory Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Hyperaldosteronism 1Colorectal Neoplasms 1Advanced Cancer 1

Interventions

enzalutamide 6radium Ra 223 dichloride 5Docetaxel 2Abiraterone Acetate 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1quemliclustat 1pembrolizumab 1atezolizumab 1apalutamide 1Standard of Care 1Radium-223 1Prednisone 1Nivolumab 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms, Castration-Resistant × Abiraterone Acetate × Clear all
NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Pfizer

Completed
2,731 enrolled 14 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05520138 2024-09-27

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Pfizer

Completed
5,506 enrolled 11 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡